Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

elotuzumab

- PMLiVE

J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

The formulation significantly reduces administration time compared to the approved intravenous version

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

- PMLiVE

Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma

An estimated 5,900 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Sanofi’s Sarclisa granted EC approval to treat newly diagnosed multiple myeloma

Approximately 46,000 cases of the disease are expected to be diagnosed in Europe in 2025

- PMLiVE

Innovative Trials appoints first Non-Executive Chair

John Watkinson is the new Non-Exec Chair as Innovative Trials targets significant business growth

Innovative Trials

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

- PMLiVE

J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

The deal gives the company access to a range of central nervous system disorder drugs

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

- PMLiVE

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal

The inflammatory skin disorder affects more than 9.6 million children and 16.5 million adults in the US

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by EC for EGFR-mutated lung cancer

Alterations in EGFR are among the most common driver mutations in NSCLC patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links